Compare Byrna Technologies Inc (BYRN) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs McKesson Corporation — how do they compare? Byrna Technologies Inc trades at $4.32 (market cap $106.74M), while McKesson Corporation trades at $880.33 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 985× Byrna Technologies Inc's market cap, and McKesson Corporation pays a 0.42% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | MCK | |
|---|---|---|
Market Cap | $106.74M | $105.14B |
Sector | Technology | Health |
52-Week High | $27.63 | $995.69 |
52-Week Low | $3.18 | $659.01 |
Enterprise Value | $98.35M | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.34, down 10.52% in 24 hours, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss in 2026 with a negative net income margin of -3.39%, though it maintains a strong gross profit margin of 52.51%. Recent leadership appointments aim to bolster marketing and retail expansion, while Q2 2026 earnings missed estimates with a loss of $0.44 per share.
The outlook is challenged by recent earnings misses and declining revenue, but analyst consensus remains bullish with 71% buy ratings. Key risks include execution in sales turnaround and competitive pressures. Upside depends on successful implementation of new growth initiatives and improved financial performance in upcoming quarters.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
